Amgen Canada has announced EVENITY’s (romosozumab) inclusion in public formularies, marking a significant step in osteoporosis care for postmenopausal women.
EVENITY has been listed for reimbursement on nine of Canada’s public formularies. With this announcement most postmenopausal women in Canada will be able to access this biologic treatment which received Health Canada approval in 2019.
Click here to visit AMGEN Canada and read the full release.
To learn more about osteoporosis treatments visit https://osteoporosis.ca/treatments/
